Strong Core, Transformative Growth Investor Day 2025 November 12 Safe harbor statement Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timi ...

Prelude Therapeutics (NasdaqGS:PRLD) Q3 2025 Earnings Call November 12, 2025 08:00 AM ET Speaker3Morning, everyone, and welcome everyone to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now turn the call over to Prelude's Chief Financial Officer and Chief Legal Officer, Bryant Lim. Please go ahead.Speaker0Thank you, Operator. During today's call, we will make forward-looking statements based on current expecta ...

Humacyte (NasdaqGS:HUMA) Q3 2025 Earnings Call November 12, 2025 08:00 AM ET Speaker2Good morning ladies and gentlemen and welcome to the Humacyte third quarter results conference call. Currently all participants are in a listen only mode. Later we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I'll now turn the call over to Tom Johnson with LifeSci Advisors. Please go ahead.Speaker4Thank you, operator. Before we p ...

The next phase of Vaca Muerta-driven growth VISTA ENERGY INVESTOR DAY NOVEMBER 12th, 2025 About projections and forward-looking statements 02 Additional information about Vista Energy, S.A.B. de C.V., a sociedad anónima bursátil de capital variable organized under the laws of Mexico (the "Company" or"Vista") can be found in the "Investors" section on the website at www.vistaenergy.com. This presentation does not constitute an offerto sell or a solicitation of any offerto buy any securities of the Company, i ...

Financial Data and Key Metrics Changes - The company ended Q3 2025 with cash totaling $5.9 million, an increase from $3.7 million as of December 31, 2024 [11] - The net loss for Q3 2025 was $2 million, or $1.23 per diluted share, compared to a net loss of $2.8 million, or $3.45 per diluted share for Q3 2024 [14] - For the nine months ended September 30, 2025, the net loss was $6.4 million, or $5.01 per diluted share, compared to a net loss of $11.3 million, or $14.23 per share for the same period in 2024 [14] Business Line Data and Key Metrics Changes - Research and development expenses for Q3 2025 were $0.4 million, down from $1.2 million in Q3 2024, primarily due to a decrease in manufacturing and consulting costs [11][12] - General and administrative expenses remained consistent at $1.6 million for Q3 2025 compared to Q3 2024, with a slight decrease in compensation-related costs offset by an increase in legal fees [12] Market Data and Key Metrics Changes - The company regained compliance with NASDAQ listing requirements after a 1-for-20 reverse stock split on August 4, 2025 [4][5] - Acurx has obtained multiple patents for its DNA polymerase 3C inhibitors, including a new patent granted by the Australian Patent Office [5][8] Company Strategy and Development Direction - The company is focused on advancing its ibezapolstat program, which has shown promising results in treating C. diff infections [9][10] - Acurx is pursuing funding opportunities for a phase three clinical trial program for ibezapolstat and is considering alternative pathways for success [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the macroeconomic environment and industry challenges while continuing to strengthen ibezapolstat's competitive profile [10] - The company recognizes November as C. diff Awareness Month and supports initiatives for education and prevention [10] Other Important Information - The company has FDA QIDP and FAST TRACK designations for ibezapolstat, which could significantly impact the economic burden of C. diff infections in the U.S. [10] - Acurx is actively engaged in scientific collaborations, with recent publications highlighting the structural biology of ibezapolstat [8] Q&A Session Summary Question: Potential for FDA to prioritize domestically manufactured novel antibiotics - Management sees potential for increased prioritization but noted uncertainty regarding the PASTOR Act and its impact on antibiotic funding [18][19] Question: Impact of proposed clinical priority review voucher framework - The regulatory approach and commercial strategy will remain the same, with plans to utilize the program at the appropriate time [21][22] Question: Filing for approval based on phase two ibezapolstat data - Management indicated that a safety database is required, and phase three trial data will be necessary for regulatory approval [23][25] Question: Timing around potential partnership discussions - Management expressed optimism about potential partnership news by the next earnings call but could not provide specific timelines [36][37] Question: QIDP and FAST TRACK designation expectations - Once obtained, these designations are maintained indefinitely without specific movement requirements [38] Question: Future operational expenses - Management anticipates that operational costs will continue to gradually decrease while maintaining a steady financial position [39]

Financial Performance - Q3 2025 revenues reached $15.3 million, a significant increase compared to $4.5 million in Q3 2024[25] - Year-to-date (YTD) revenues for 2025 totaled $42.4 million, approximately 2.3 times greater than the same period in 2024[8, 28] - Q3 2025 saw a cash burn of $14.0 million[8, 28] - Operating expenses were reduced to $18.1 million in Q3 2025, a 30% decrease from $26.0 million in Q3 2024[25] Business Development & Technology - A major commercial vehicle OEM selected Innoviz for series production of L4 autonomous class-8 semi trucks[7, 12, 29] - Innoviz has begun shipping InnovizTwo sensors for the OEM's data collection trucking fleet[12] - Innoviz is developing software modifications to address the OEM's unique vehicle integration requirements[12] - InnovizSMART-based perimeter security solution outperformed existing radar/camera systems in auditor testing[7, 16, 29] - Innoviz unveiled InnovizThree, designed for behind-the-windshield integration with a smaller form factor, better performance, and lower power consumption[8] Targets - The company is aiming for revenues between $50 million and $60 million[22] - The company is aiming for NRE Bookings between $30 million and $60 million[22]

Summary of Prime Medicine Conference Call on Wilson Disease Company Overview - **Company**: Prime Medicine - **Focus**: Development of prime editing technology for genetic diseases, specifically targeting Wilson disease and other liver-related conditions [3][6][11] Industry Context - **Disease**: Wilson disease, a genetic disorder caused by mutations in the ATP7B gene, leading to copper accumulation in the body [21][24] - **Current Treatments**: Existing therapies include chronic chelation therapy and dietary restrictions, which are burdensome and often ineffective [30][37] Key Points and Arguments 1. **Strategic Focus**: Prime Medicine is concentrating on Wilson disease due to its high unmet medical need and the absence of curative therapies [8][10] 2. **Prime Editing Technology**: This next-generation gene editing technology allows precise and permanent correction of genetic mutations, offering the potential for durable cures [11][12][38] 3. **Preclinical Data**: Recent preclinical studies demonstrate that prime editing can revert Wilson disease to a normal phenotype, showcasing the technology's transformative potential [9][40][46] 4. **Market Opportunity**: The global market for Wilson disease treatments is estimated to exceed $20 billion, with potential to reach $40 billion, given the prevalence of the disease in the U.S., Europe, and Japan [20][21] 5. **Patient Population**: Approximately 25,000 patients in the U.S., Europe, and Japan are considered addressable for prime editing therapies, with a focus on the most prevalent mutations (H1069Q and R778L) [18][19] 6. **Clinical Development Plans**: Prime Medicine plans to file an IND for Wilson disease in 2026, with initial human data expected in 2027 [16][48] 7. **Safety and Efficacy**: Preclinical studies indicate a favorable safety profile with no off-target effects and high editing efficiency, achieving over 80% correction in animal models [39][42][41] 8. **Long-term Vision**: The company aims to transition from managing symptoms to providing a one-time curative treatment, fundamentally changing patient care for Wilson disease [37][50] Additional Important Insights - **Challenges in Current Treatments**: Current therapies have significant non-adherence rates (30-50%) and can lead to severe side effects, highlighting the need for a more effective solution [31][78] - **Potential for Broader Applications**: The modular nature of prime editing technology allows for rapid expansion into other liver diseases and genetic disorders, enhancing the company's pipeline [15][54] - **Regulatory Considerations**: The company is preparing for regulatory filings and is focused on establishing safety and efficacy benchmarks for accelerated approval [91][92] This summary encapsulates the critical insights from the conference call, emphasizing Prime Medicine's innovative approach to treating Wilson disease and the broader implications for genetic therapies.

Summary of Gold Fields Capital Markets Day Company Overview - **Company**: Gold Fields (NYSE:GFI) - **Event**: 2025 Capital Markets Day - **Date**: November 12, 2025 Key Industry Insights - Gold Fields aims to position itself as a long-term, reliable gold producer, focusing on sustainable performance rather than short-term hype [2][3] - The company emphasizes a multi-generational business model, with a clear five-year plan to enhance its production profile and extend the life of its assets [3][4] Core Business Strategies - **Production Profile**: Gold Fields believes it has a best-in-class production profile and aims to outperform its peers [3] - **Capital Allocation**: The company plans to invest significantly in its operations, with a focus on improving cash flow per share rather than merely increasing production volume [4][5] - **Safety and Culture**: A strong emphasis is placed on safety, with investments aimed at changing organizational culture to ensure safe operations [10][11] Financial Guidance - Gold Fields expects to deliver significant cash flow over the next five years, even with a conservative gold price assumption nearly $1,000 below current spot prices [5][28] - The company has set a production target of 2.5-3 million ounces by the end of the decade, with over 70% of production expected to come from its current portfolio beyond 2035 [24][29] Growth Opportunities - **Brownfields Exploration**: The company is investing over $100 million annually in Brownfields exploration, which has proven to be a cost-effective way to extend reserve life [36][37] - **Greenfields Exploration**: Gold Fields is also focusing on Greenfields exploration, targeting high-margin discoveries with the potential for significant production [40][41] - **M&A Activity**: Recent acquisitions, including the Windfall project and Gold Road, are seen as strategic moves to enhance portfolio quality and extend mine life [48][49] Capital Expenditure - Gold Fields plans to allocate approximately $2 billion in discretionary capital over the next five years, with a significant portion aimed at life extension projects [30][32] - The company is also investing in material handling systems to reduce costs and extend the life of existing operations [33][55] Market Position and Valuation - Despite a strong production and cost outlook, Gold Fields continues to trade at a relative discount compared to its peers, presenting an opportunity for future outperformance [34][35] - The company has a long history of successful operations and aims to build sustainable value for the long term [35] Conclusion - Gold Fields is committed to a strategic approach that balances immediate operational needs with long-term growth objectives, focusing on safety, capital efficiency, and portfolio quality to drive shareholder value [20][35]

Financial Data and Key Metrics Changes - System-wide sales for Q3 2025 were $238.2 million, a decrease of 0.8% year-over-year, primarily due to closed centers [19] - Same-store sales grew by 20 basis points year-over-year [19] - Adjusted EBITDA increased by 9.6% to $20.2 million from $18.4 million in the prior year [22] - Adjusted EBITDA margin improved by 400 basis points to 37.2% [22] - Total revenue decreased by approximately $1.2 million, or 2.2%, primarily due to lower contributions from wholesale product and retail revenue [20] - Gross margin increased modestly to 73.3% [21] - Adjusted net income rose by 14.2% to $10.7 million from $9.3 million last year [22] Business Line Data and Key Metrics Changes - The company opened three growth centers during the quarter and closed nine, resulting in six net closures [20] - The focus on traffic growth among both new and existing guests has been emphasized, with retention stable quarter-over-quarter [8][10] Market Data and Key Metrics Changes - The company ended Q3 with 1,053 centers, down 1% year-over-year [20] - Com trends were strong through July and mid-August before softening in the latter half of August and September [19] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving sales through traffic growth, improving four-wall profitability for franchisees, and pursuing disciplined, profitable expansion [6][12] - A new brand agency has been brought on to refine the brand and connect with high-value audiences, with foundational work already completed [12][44] - The company expects to return to positive net center growth by year-end 2026 [17] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed full-year financial guidance, expecting system-wide sales of $940-$950 million and same-store sales to be flat to up 1% for the full year [25] - The company is optimistic about the progress made in marketing and operational capabilities, which are expected to strengthen guest engagement and traffic [19][24] - Management noted that new guest acquisition remains pressured but anticipates improvement in 2026 [25][44] Other Important Information - The company narrowed its closure range to between 35 and 40 for the year, reflecting timing shifts in anticipated closures [24] - The company has a $40 million revolver fully undrawn and ended the quarter with $73.6 million in cash [23] Q&A Session Summary Question: Can you quantify the lift seen from revamped marketing efforts? - Management noted that they have improved contactability from 38% to 60% of guests, which has allowed for better engagement and improved frequency [30] Question: What trends are observed in Wax Pass sales and regional performance? - Wax Pass sales have seen a slight year-over-year uptick, with stability in the core guest base, while California has shown improvement compared to New York, Philadelphia, and DC [32][33] Question: What are the expectations for center openings and closures moving forward? - Management indicated that closures are primarily low-volume units due to various factors, and they expect to return to net positive growth by the end of 2026 [36][37] Question: What is the outlook for new guest acquisition? - Management highlighted that robust data analytics and a fresh brand identity are expected to enhance new guest acquisition efforts [41][44] Question: What factors might affect Q4 performance? - Management acknowledged timing situations that may impact year-over-year growth but remains confident in meeting full-year guidance [40]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported a 19% year-over-year revenue growth, reaching $12.2 million, driven by increased production from its facilities in Georgia, Texas, and Washington [17] - The adjusted EBITDA loss improved to $7.2 million from $8.4 million in Q3 of the previous year, indicating meaningful year-over-year progress [17] - The net loss for Q3 decreased to $26.4 million from $34.3 million in the prior year, primarily due to lower interest expenses from a debt restructuring [18] Business Line Data and Key Metrics Changes - The Texas facility completed its reconfiguration and reached full harvestable capacity, effectively doubling its productive output [6] - Labor productivity increased by approximately 19%, while direct labor costs per pound decreased by about 17%, showcasing operational efficiency improvements [7] - The company anticipates yield increases of over 10% following ongoing optimization efforts across its facilities [9] Market Data and Key Metrics Changes - The packaged salad market is projected to grow at an annual rate of 8.6% through 2029, with the company launching new family-sized salad kits to meet consumer demand in this segment [13] - The company expanded its distribution in the Pacific Northwest, launching a new 10-ounce Romano salad kit across 89 Walmart stores, which is expected to enhance its market presence [12] Company Strategy and Development Direction - The company is focusing on building long-term supply partnerships with major retailers, transitioning discussions from exploratory to strategic [4][5] - There is an emphasis on optimizing product mix and pricing architecture to align with marketplace needs, which is expected to improve overall unit economics [11][16] - The company aims to achieve positive adjusted EBITDA by early 2026, driven by volume growth, operational efficiency, and cost discipline [20] Management's Comments on Operating Environment and Future Outlook - Management highlighted a significant shift in market perception of controlled environment agriculture (CEA), now viewed as essential infrastructure rather than an emerging technology [16] - The company is entering Q4 with enhanced operational capacity and stronger commercial momentum than ever before, positioning itself to capitalize on market opportunities [21] Other Important Information - The company has achieved nearly $8 million in annualized cost reductions through the first nine months of the year, with additional initiatives expected to yield $1.5 million to $2 million in further savings [10][20] - A patent application related to optimizing growing processes using computer vision and AI is anticipated to be issued soon, which could enhance production efficiency [9] Q&A Session Summary Question: What are the expectations for revenue growth and adjusted EBITDA? - Management expects revenue growth and product mix optimizations to be key levers for achieving positive adjusted EBITDA, anticipated in early 2026 [20] Question: How is the company addressing operational efficiency? - The company is implementing tower upgrades and automated harvesting, which are expected to improve cost structures and operational efficiency over time [20]